Live news related to MAAT PHARMA stock (FR0012634822): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The stock of the Lyon-based biotech company recorded one of its strongest daily gains in several months, reaching 6.02 euros. This rebound follows a s…
MaaT Pharma announces the publication of the CHRONOS study, a multicenter retrospective analysis evaluating third-line treatments in 59 patients with …
MaaT Pharma releases its annual results for 2025 and updates on its microbiome therapy portfolio. The year 2026 is set to be pivotal with the ongoing …
MaaT Pharma announced on Monday the presentation of the final results of the pivotal ARES trial evaluating MaaT013 in acute gastrointestinal graft-ver…
MaaT Pharma announces the presentation of clinical data related to its therapeutic portfolio at the 2026 Annual EBMT Congress, to be held from March 2…
MaaT Pharma's stock increases by 3.2% this Thursday morning to 7.10 euros, after closing at 6.88 euros the previous day. This rebound occurs in a cont…
Lyon-based biotech MaaT Pharma has announced the launch of the IMMUNOLIFE clinical trial, a Phase 2 study assessing MaaT033 in combination with cemipl…
MaaT Pharma has disclosed the final results of its phase 3 clinical trial, ARES, assessing MaaT013 for the treatment of refractory acute graft-versus-…
MaaT Pharma, specializing in the development of microbiotic therapies, has announced the successful completion of its capital increase amounting to €9…
MaaT Pharma has announced the launch of a global offering of ordinary shares amounting to approximately €9 million, according to a press release dated…
